|
MediVas Announces Achievement of Milestone in Connection
with Merck Agreement
SAN DIEGO, CA, April 3
--
MediVas, LLC, a developer
of novel drug delivery platforms, today announced the achievement of a
milestone relating to its previously disclosed agreement with Merck &
Co., Inc. The milestone was
specifically connected to one of the several orally available biologics
that are the focus of the collaboration. Under the terms of the agreement,
MediVas will receive an undisclosed cash payment from Merck for achievement
of the milestone.
“We
are pleased to have achieved this milestone ahead of schedule,” said
Kenneth W. Carpenter, MediVas’ President and CEO. “This is an important
accomplishment for MediVas and further demonstrates the capabilities of our
polymer delivery platform, particularly for the delivery of biologics. We look forward to continuing our
fruitful relationship with Merck and to moving on to the successful
completion of other important milestones during the collaboration.”
About
MediVas: Using
its proprietary family of biodegradable and biocompatible polymers, MediVas
has developed unique platforms for the delivery of biologics. MediVas is utilizing its novel
polymer technology in collaboration with some of the world's largest
pharmaceutical companies, as well as on its own internal product
development efforts, to create groundbreaking medical advancements. By combining therapeutic proteins
and other biologics with a MediVas polymer, delivery routes that were
previously unattainable, such as oral, intranasal, inhaled or subcutaneous
injection, can now be achieved.
With these routes of delivery then available, MediVas’
delivery system can make the administration of the biologic more
convenient, more efficacious and safer, leading to higher patient
compliance and overall better health.
Contact:
MediVas, LLC
Victor E. Vilaplana
Director, Business Development
(858) 622-2005
vvilaplana@medivas.com
© MediVas, LLC
|